Cerity Partners LLC raised its position in shares of Organon & Co. (NYSE:OGN – Free Report) by 94.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 667,340 shares of the company’s stock after acquiring an additional 323,308 shares during the quarter. Cerity Partners LLC’s holdings in Organon & Co. were worth $12,766,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc boosted its position in Organon & Co. by 200.2% during the second quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock valued at $25,000 after acquiring an additional 805 shares during the last quarter. Prospera Private Wealth LLC bought a new stake in Organon & Co. during the third quarter valued at $25,000. William B. Walkup & Associates Inc. bought a new stake in Organon & Co. during the second quarter valued at $31,000. Atlas Capital Advisors LLC boosted its position in Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock valued at $46,000 after acquiring an additional 2,147 shares during the last quarter. Finally, Abich Financial Wealth Management LLC boosted its position in Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after acquiring an additional 2,315 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.
Organon & Co. Price Performance
Shares of OGN opened at $16.17 on Tuesday. The business’s fifty day moving average is $17.52 and its 200 day moving average is $19.74. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock has a market cap of $4.16 billion, a P/E ratio of 3.21, a P/E/G ratio of 0.72 and a beta of 0.84.
Organon & Co. Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th will be paid a $0.28 dividend. The ex-dividend date of this dividend is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.93%. Organon & Co.’s payout ratio is presently 22.22%.
Analysts Set New Price Targets
A number of analysts have commented on the stock. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and upped their price target for the company from $18.00 to $20.00 in a research report on Friday, September 6th. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th.
Check Out Our Latest Analysis on OGN
About Organon & Co.
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Further Reading
- Five stocks we like better than Organon & Co.
- How to Plot Fibonacci Price Inflection Levels
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- What is Insider Trading? What You Can Learn from Insider Trading
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- Bank Stocks – Best Bank Stocks to Invest In
- Discover the 3 Best Performing Stocks That Went Public in 2024
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Free Report).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.